Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Viking Therapeutics
Thumbnail
March 03, 2023

Spotlight – What's next in Nash

The next few months will see some important mid-stage Nash results, from Viking, 89Bio, Northsea and others.

December 22, 2022

Spotlight - Biotech tries everything it can in Nash

The Nash pipeline is pharmacologically diverse, and some projects look like very long shots.

Article image
Vantage logo
December 21, 2022

Catalysts ahead for the smaller players

Calliditas heads for confirmatory data in IgA nephropathy, while Viking and 89Bio are set for key readouts in Nash.

Article image
Vantage logo
December 19, 2022

Madrigal changes the tune in Nash

A smash hit in resmetirom’s pivotal trial sets up an accelerated approval filing next year.

Article image
Vantage logo
January 31, 2022

Madrigal’s Maestro result puts the focus on Nash

Resmetirom’s first pivotal liver disease study reminds the markets about the third quarter’s Nash readout, but investors wanted more.

Article image
Vantage logo
January 24, 2022

Early-stage US clinical holds spread

Article image
Vantage logo
October 07, 2019

NGM’s Nash data delivers, but not quite enough

Article image
Vantage logo
April 12, 2019

EASL 2019 – Novo buys into Gilead’s Nash combo plan

Today’s deal will see the companies take a triple combination into clinical trials.

Article image
Vantage logo
April 12, 2019

Upcoming events – a legal verdict for Enbrel and a clinical one for Cymabay

Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.

Article image
Vantage logo
April 11, 2019

EASL 2019 – Viking to push the limits of its Nash contender

Encouraging results from Viking Therapeutics’ lead Nash project have prompted the company to ask how low it can go.

Article image
Vantage logo
March 28, 2019

EASL 2019 preview – Viking and Spring Bank abstracts pique early interest

High-profile presentations from the likes of Intercept and Alnylam remain under wraps before Europe’s biggest liver disease conference next month, but the early abstract…

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up